Study of the cost variation analysis of anti-epileptic drugs available in different brands in Indian pharmaceutical market

Hansraj Kumar1*, Uma Shankar Prasad Kesari2, Rajiv Kumar3

1Department of Pharmacology, SNMMCH, Dhanbad, Jharkhand, India
2Department of Pharmacology, RIMS, Ranchi, Jharkhand, India
3Department of Pharmacology, HI-TECH Medical College, Rourkela, Odisha, India

Received: 03 March 2021
Accepted: 05 April 2021

*Correspondence:
Dr. Hansraj Kumar,
Email: dr.hansrajkumarpharma@gmail.com

ABSTRACT

Background: The aim of this study was to analyze the cost ratio and percentage cost variations in different brands of the commonly prescribed anti-epileptic drugs available in Indian pharmaceutical market.

Methods: The maximum and minimum price of each brand of the drug given in Indian rupees (INR) was noted by using CIMS January to April 2020 edition and drug today April to June 2020 volume 1. The cost ratio and the percentage cost variation for individual drug brands was calculated. The cost of one bottle in case of 100 ml syrup and 10 tablets/capsules was calculated in case of oral drugs and the cost of one 1 vial or ampoule was noted in case of injectable drugs. At last the cost ratio and percentage cost variation of various brands was compared.

Results: After calculation of cost ratio and percentage cost variation for each brand of anti-epileptic drug tablet clonazepam (2 mg) shows highest cost ratio and percentage cost variation as 10.41 and 941.66, carbamazepine (200 mg SR tablet) shows lowest cost ratio and percentage cost variation as 1.09 and 9.32.

Conclusions: Epilepsy is the most common neurological disorder and epileptic drugs are to be prescribed for prolonged period. If a costly brand is prescribed, the patients have to pay more money unnecessarily for their treatment. There is a wide difference in the cost of different brands of anti-epileptic drugs available in India. The clinicians prescribing these drugs should be aware of these variations in cost to reduce the cost of drug therapy.

Keywords: Anti-epileptic drugs, Percentage cost variation, Cost ratio

INTRODUCTION

Epilepsy is a group of neurological disorders which is characterized by seizures, loss of consciousness, muscular contraction.1 The cause of most cases of epilepsy is unknown.2 Some cases occur as the result of brain injury, stroke, brain tumors, infections of the brain and birth defects through a process known as epileptogenesis.2 Known genetic mutations also causes some cases of epilepsy.3 The diagnosis involves ruling out other conditions such as alcohol withdrawal or electrolyte problems.3 Epileptic seizures are the result of excessive and abnormal neuronal activity in the cortex of the brain.4 In 2015, about 39 million people have epilepsy.3 Nearly 80% of cases occur in the developing world. In 2015, it resulted in 125,000 deaths up from 112,000 deaths in 1990.6 Epilepsy is more common in older people.7 In the developed world, onset of new cases occurs most frequently in babies and the elderly.8 In the developing world, onset is more common in older children and young adults, due to differences in the frequency of the underlying causes.9 The diagnosis of epilepsy is typically made based on observation of the seizure onset and the
underlying cause. An electroencephalogram (EEG) to look for abnormal patterns of brain waves and neuroimaging (CT scan or MRI) to look at the structure of the brain are also usually part of the workup. Video and EEG monitoring may be useful in difficult cases. The mainstay treatment of epilepsy is anticonvulsant medications, possibly for the person’s entire life. The choice of anticonvulsant is based on seizure type, epilepsy syndrome, other medications used, other health problems, and the person’s age and lifestyle. A single medication is recommended initially. If this is not effective, switching to a single other medication is recommended. There are a number of medications available including phenytoin, carbamazepine and valproate. Low-quality evidence suggests that phenytoin, carbamazepine and valproate may be equally effective in both focal and generalized seizures. Controlled release carbamazepine appears to work as well as immediate release carbamazepine and may have fewer side effects. Patients from poor socioeconomic background must have access to the correct drug at the nominal price. Costly drugs can lead to economic burden which results in decreased compliance or even non-compliance. Non-compliance leads to incomplete treatment which tends to increase morbidity. There is a gross variation in the cost of different brands of anti-epileptic drugs available in Indian pharmaceutical market. Increase in the patient medication cost was found to be associated with decrease adherence to prescription medication. Hence the present study was conducted to evaluate the cost variation amongst the different brands of anti-epileptic drugs available in Indian pharmaceutical market.

METHODS

Price in INR of anti-epileptic drugs manufactured by different pharmaceutical companies in India, in the different strength were obtained from current index of medical specialists (CIMS) January to April 2020 edition and from drug today April to June 2020, volume 1 as they are readily available source of drug information and were updated regularly. The cost of 10 tablets/capsules, syrup of one bottle and that of one ampoule/vial were calculated. The cost of drugs were also crosschecked at pharmacy or retail drug store. Difference in the maximum and minimum price of the same drug formulation manufactured by different pharmaceutical companies and percentage variations in prices were calculated. The cost of injectable drugs and oral drugs in forms of tablet, capsule and syrup was calculated separately. The cost ratio, calculated as the ratio of the costlier brand to that of the cheapest brand of the same drug, calculated as follows,

\[
\text{Cost ratio} = \frac{\text{Price of the costliest brand}}{\text{Price of the least costly brand}}
\]

The percentage cost variation of each drug should be calculated as follows,

\[
\text{Percentage cost variation} = \frac{\text{maximum cost} - \text{minimum cost}}{\text{minimum cost}} \times 100.
\]

Maximum percentage cost variation and cost ratio of a particular drug was noted down. Minimum percentage cost variation and cost ratio of a particular drug was noted down.

Inclusion criteria

Drugs belonging to group of anti-epileptics only was included. Dosage form of anti-epileptic drugs being capsule/tablet, syrup, ampoule/vial were included. Drugs belong to branded manufacturing companies, drugs of same and different strength was also included.

Exclusion criteria

Anti-epileptic drugs in combinations with other drugs and drugs belonging to bogus manufacturing companies were excluded.

RESULTS

Table clonazepam (2 mg) shows highest cost ratio and percentage cost variation as 10.41 and 941.66, tablet carbamazepine (200 mg SR tablet) shows lowest cost ratio and percentage cost variation as 1.09 and 9.32. We preferred those drugs who possessed cost ratio less than 2 and percentage cost variation less than 100.

| Drugs           | Dose      | Number of brands | Maximum price (rupees) | Minimum price (rupees) | Price ratio | % price variation |
|-----------------|-----------|------------------|------------------------|------------------------|-------------|------------------|
| Carbamazepine   | 200 mg CR tablet | 3 | 21.40 | 14.30 | 1.49 | 49.65 |
|                 | 200 mg ER tablet | 2 | 23.50 | 15.79 | 1.48 | 48.82 |
|                 | 200 mg SR tablet | 2 | 15 | 13.72 | 1.09 | 9.32 |
|                 | 200 mg tablet   | 20 | 21.40 | 11 | 1.94 | 94.54 |
|                 | 400 mg CR tablet | 2 | 41.70 | 26.50 | 1.57 | 57.35 |
|                 | 400 mg ER tablet | 2 | 45.75 | 31.02 | 1.47 | 47.48 |
|                 | 400 mg tablet   | 8 | 41.70 | 24.24 | 1.72 | 72.02 |

Continued.
DISCUSSION

The Indian market has over 100,000 formulations and there is no system of registration of medicines. More than one company sells a particular drug under different brand names apart from the innovator company. This situation has led to greater price variation among drugs marketed. These wide variations in the prices of different formulations of the same drug have severe economic implications in India. Unlike developed countries, people in developing countries pay the cost of medicines out-of-pocket. Many poor people frequently face a choice between buying medicines or buying food or other necessities due to limited resources and high pricing of drug. So, medicine prices do matter. In India more than 80% health financing is borne by patients. Studies have shown that providing a manual of comparative drug prices annotated with prescribing advice to physicians reduced their patients drug expense especially in a disease like hypertension which needs long term treatment. Costs of drugs are controlled by the drug cost control order 2013 (DPCO). Hence, it was need to draw attention to the prices of various drug formulation brands available to reduce the cost of therapy. The treating physician should be made aware of the cheapest drug available among the various brands so that the patient bears lesser burden of treatment cost.

CONCLUSION

Nowadays prices of few drugs are under government control through DPCO (drug price control order). The physician should always remember that he should not avoid treating the patients with a particular drug because it is expensive and should rather balance his therapeutic decisions in prescribing a particular drug by considering the patients socioeconomic status. There is a strong need to create awareness about this huge price variation among the general public, health care providers, health care payers, government agencies, policy makers, pharmacists for appropriate intervention to reduce economic burden on patients as well as the healthcare system.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: The study was approved by the Institutional Ethics Committee

| Drugs          | Dose                        | Number of brands | Maximum price (rupees) | Minimum price (rupees) | Price ratio | % price variation |
|----------------|-----------------------------|------------------|------------------------|------------------------|-------------|------------------|
| Sodium valproate | 100 mg tablet               | 11               | 11.21                  | 6.50                   | 1.72        | 72.46            |
|                | 200 mg tablet               | 14               | 42                     | 21.85                  | 1.92        | 92.21            |
|                | 200 mg/5 ml syrup           | 5                | 65                     | 47.50                  | 1.36        | 36.84            |
|                | 250 mg tablet               | 4                | 64                     | 45                     | 1.42        | 42.22            |
|                | 500 mg tablet               | 13               | 90                     | 46.81                  | 1.92        | 92.26            |
|                | 500 mg ER tablet            | 5                | 118                    | 58                     | 2.03        | 103.44           |
|                | 500 mg CR tablet            | 6                | 90                     | 32                     | 2.81        | 181.25           |
| Phenytoin      | 50 mg tablet                | 4                | 13.50                  | 7.26                   | 1.85        | 85.95            |
|                | 100 mg tablet               | 10               | 21.1                   | 5.71                   | 3.69        | 269.52           |
|                | 300 mg ER tab/cap           | 3                | 59                     | 50.19                  | 1.17        | 17.55            |
| Pregabalin     | Inj 50 mg/ml (2 ml ampoule) | 4                | 120.90                 | 58                     | 2.08        | 108.44           |
|                | 75 mg capsule               | 21               | 97                     | 54.89                  | 1.76        | 76.71            |
|                | 150 mg capsule              | 13               | 159                    | 115                    | 1.38        | 38.26            |
|                | 0.25 mg tablet              | 24               | 22                     | 9.10                   | 2.41        | 141.75           |
| Clonazepam     | 0.5 mg tablet               | 44               | 36                     | 9.90                   | 3.63        | 263.63           |
|                | 1 mg tablet                 | 25               | 43                     | 18.29                  | 2.35        | 678.29           |
|                | 2 mg tablet                 | 31               | 75                     | 7.20                   | 10.41       | 941.66           |
| Lamotrigine    | 25 mg tablet                | 9                | 58                     | 21                     | 2.76        | 176.19           |
|                | 50 mg tablet                | 9                | 90                     | 39                     | 2.30        | 130.76           |
|                | 100 mg tablet               | 8                | 157                    | 69                     | 2.27        | 127.53           |
| Gabapentin     | 100 mg tab/cap              | 5                | 47.50                  | 42                     | 1.13        | 13.09            |
|                | 300 mg tab/cap              | 12               | 312.87                 | 69.90                  | 4.47        | 347.59           |
| Levetiracetam  | 250 mg tablet               | 9                | 82                     | 44                     | 1.86        | 86.36            |
|                | 500 mg tablet               | 17               | 164                    | 75                     | 2.18        | 118.66           |
|                | Inj 100 mg/ml               | 6                | 147                    | 40                     | 3.67        | 267.5            |
| Topiramate     | 25 mg tablet                | 4                | 56                     | 30                     | 1.86        | 86.66            |
|                | 50 mg tablet                | 6                | 87                     | 58                     | 1.5         | 50               |
|                | 100 mg tablet               | 3                | 15                     | 108                    | 1.42        | 42.59            |
REFERENCES

1. Chang BS, Lowenstein DH. Epilepsy. New England J Med. 2003;349(13):1257-66.
2. Epilepsy Fact sheet. WHO. February 2016. Archived from the original on 11 March 2016. Retrieved 4 March 2016
3. Dan L, Fauci A, Kasper D, Hauser S, Jameson JL, Loscalzo J. 369 Seizures and Epilepsy. Harrison's principles of internal medicine 18th ed. New York, NY: McGraw-Hill; 2011: 3258.
4. Fisher R, van-Emde BW, Blume W, Elger C, Genton P, Lee P, et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia. 2005;46(4):470-2.
5. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1545-602.
6. GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1459-544.
7. Holmes, Thomas R, Browne, Gregory L. Handbook of epilepsy. 4th ed. Philadelphia: Lippincott Williams and Wilkins; 2008: 7.
8. Wyllie. In: Cascino GD, Gidal BE, Goodkin HP, eds. Wyllie's treatment of epilepsy: principles and practice. 5th ed. Philadelphia: Wolters Kluwer/Lippincott Williams and Wilkins; 2010.
9. Newton CR, Garcia HH. Epilepsy in poor regions of the world. Lancet. 2012;380(9848):1193-201.
10. National Clinical Guideline Centre. The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. Nat Instit Heal Clinic Excell. 2012:21-8.
11. Wyllie E, In: Cascino GD, Gidal BE, Goodkin HP, eds. Wyllie's Treatment of epilepsy: principles and practice. Lippincott Williams and Wilkins; 2012: 187.
12. National Clinical Guideline Centre. The epilepsies: The diagnosis and management of the epilepsies in adults and children in primary and secondary care. Nat Instit Heal Clinic Excell. 2012:57-83.
13. Sarah JN, Anthony GM, Jennifer W, Catrin TS. Phenytoin versus valproate monotherapy for partial onset seizures and generalised onset tonic-clonic seizures: an individual participant data review. Cochr Syst Rev. 2016;4.
14. Graham P, Matthew S, Alexandra R, Anthony GM. Immediate-release versus controlled-release carbamazepine in the treatment of epilepsy. Cochr Database Syst Rev. 2016;12:7124.
15. Eaddy MT, Cook CL, O’Day K, Burch SP, Cantrell CR. How patients cost-sharing trends affects adherence and out comes: a literature review: PT. 2012;37(1):45-55.
16. Thomas M. Rational drug use and essential drug concept. In: Parthasarathi G, Nyfort Hasen K, eds. A textbook of clinical pharmacy practice. 1st ed. Hyderabad: Orient Longman; 2004: 723.
17. Rataboli PV, Garg A. Confusing brand names: nightmare of medical profession. J Postgrad Med. 2005;51(1):13-6.
18. Drug Cost Control. Government of India, 2013. Available at: http://www.nppaindia.nic.in/DPCO2013.Pdf. Accessed on 17 February 2021.
19. Vieira JL, Portal VL, Moriguchi EH. How much do we pay for a benefit? A descriptive cost analysis of the use of statins. The need for a national cost-effectiveness analysis. Arq Bras Cardiol. 2001;76(5):409-18.

Cite this article as: Kumar H, Kesari USP, Kumar R. Study of the cost variation analysis of anti-epileptic drugs available in different brands in Indian pharmaceutical market. Int J Basic Clin Pharmacol 2021;10:523-6.